Vitae Pharmaceuticals, Inc 4
4 · Vitae Pharmaceuticals, Inc · Filed Oct 25, 2016
Insider Transaction Report
Form 4
JUNIUS DANIEL M
Director
Transactions
- Disposition to Issuer
Stock Option (Right to Buy)
2016-10-25$9.63/sh−20,000$192,600→ 0 totalExercise: $11.37Exp: 2026-07-26→ Common Stock (20,000 underlying)
Footnotes (2)
- [F1]Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated September 13, 2016, by and among the Issuer, Allergan Holdco US, Inc. and Augusta Merger Sub, Inc., each outstanding option to purchase shares of the Issuer's common stock, whether or not exercisable or vested, was cancelled and the holder thereof became entitled to receive an amount in cash determined by multiplying (A) the excess, if any, of $21.00 over the exercise price per share of the common stock underlying such stock option by (B) the number of shares of common stock subject to such stock option.
- [F2]This option, which provided for vesting in equal quarterly installments over three years following July 27, 2016, was cancelled and the Reporting Person became entitled to receive an amount in cash per the terms of the Merger Agreement, as described in footnote (1) above.